Menu
Search
|

Menu

Close
X

Intersect ENT Inc XENT.OQ (NASDAQ Stock Exchange Global Market)

33.70 USD
-1.35 (-3.85%)
As of Jul 14
chart
Previous Close 35.05
Open 34.95
Volume 67,518
3m Avg Volume 65,300
Today’s High 35.05
Today’s Low 33.00
52 Week High 42.90
52 Week Low 26.92
Shares Outstanding (mil) 29.19
Market Capitalization (mil) 894.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
25
FY17
96
FY16
79
FY15
62
EPS (USD)
FY18
-0.205
FY17
-0.563
FY16
-0.888
FY15
-1.012
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
10.26
5.73
Price to Book (MRQ)
vs sector
7.90
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-16.93
14.61
Return on Equity (TTM)
vs sector
-17.07
16.34

EXECUTIVE LEADERSHIP

Lisa Earnhardt
President, Chief Executive Officer, Director, Since 2008
Salary: $539,721.00
Bonus: --
Jeryl Hilleman
Chief Financial Officer, Since 2014
Salary: $367,713.00
Bonus: --
Richard Kaufman
Senior Vice President, Chief Operating Officer, Since 2007
Salary: $342,686.00
Bonus: --
David Lehman
General Counsel, Since 2016
Salary: $350,014.00
Bonus: --
Gwen Carscadden
Chief People Officer, Since 2016
Salary: $129,639.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

1555 Adams Dr
MENLO PARK   CA   94025-1439

Phone: +1650.6412100

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

SPONSORED STORIES